AIM ImmunoTech 10-Q: Going Concern Warning, $10.0M Nine-Month Loss, 47.4M Warrants Outstanding
AIM sits 24% above its 52-week low of $0.12 on light trading volume (0.1× avg).
Summary
AIM ImmunoTech reported a $10.0 million nine-month net loss and explicitly warned that its cash only lasts into 2027, raising substantial doubt about going concern. Roughly 47.4 million warrants and 521,000 Series G preferred conversion shares remain outstanding over 39.9 million shares.
Key Events · Earnings and Guidance · AIM
-
Going Concern Warning Disclosed
Management states that recurring losses and operating cash outflows raise substantial doubt about the company's ability to continue as a going concern for at least one year from issuance of the financial statements.
-
Cash Lasts Only Into 2027
Cash, cash equivalents and marketable securities totaled $6.9 million at September 30, 2026, up from $3.0 million at December 31, 2025, but management says this funds operations only into 2027 against annual working capital needs of $7.2 million to $10.8 million.
-
Nine-Month Loss of $10.0 Million
Net loss was $9,954 thousand for the nine months ended September 30, 2026 versus $9,783 thousand a year earlier; operating cash burn was $10,240 thousand.
-
Heavy Warrant Overhang
About 47.4 million warrants plus Series G preferred convertible into 521,000 shares remain outstanding against 39,904,844 shares outstanding at September 30, 2026, so future exercises or raises would dilute existing holders significantly.
Analysis · AIM · Life Sciences
The central fact is the going-concern warning: management now states plainly that losses and operating cash burn raise substantial doubt about the company's ability to continue as a going concern within a year of issuance, and that its $6.9 million of cash and securities only funds operations into 2027. With the DURIPANC pancreatic cancer readout expected in Q1 2027, the company must raise more money before or around that data to keep going. The equity structure is already heavily loaded — roughly 47.4 million warrants plus 521,000 Series G preferred conversion shares sit on top of 39.9 million shares outstanding, so any future raise or warrant exercise dilutes existing holders further. Offsetting the risk somewhat, the balance sheet was cleaned up this year: the February 2024 Streeterville note was fully satisfied by September 3, 2026, and NYSE American listing deficiencies were resolved in June 2026.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AIM was trading at $0.15 on NYSE in the Life Sciences sector, with a market capitalization of approximately $5.9M. The 52-week trading range was $0.12 to $1.88. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.